Skip to main content
OpenTrials
Terminated

NCT Number: NCT07085468

A Study of LY3549492 in Healthy Weight Adult Participants

The main purpose of this study is to evaluate the safety and tolerability of LY3549492 in adult participants with a healthy body max index (BMI) of 22 to 25 kilograms per square meter (kg/m2).

Participation in the study will last about 13 months.

Why the study stopped: Study terminated for strategic business reasons
Terminated

Looking for future studies?

Notify Me

Key information

Conditions

Healthy Body Weight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

55 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Viacar Recherche Clinique, Greenfield Park, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Have a body mass index (BMI) within the range of 22 to 25 kilograms per square meter (kg/m2)
  • Have had a stable body weight for 3 months prior to screening

Exclusion criteria

  • Have type 1 diabetes, latent autoimmune diabetes in adults, or a history of ketoacidosis or hyperosmolar coma
  • Have:
  • type 2 diabetes and on antidiabetic therapy (except type 2 diabetes being managed with diet and/or stable dose of metformin)
  • rare forms of diabetes mellitus, or
  • hemoglobin A1c (HbA1c) >8%
  • Have poorly controlled hypertension
  • Have any of the following cardiovascular conditions within 12 months prior to screening:
  • acute myocardial infarction
  • stroke
  • unstable angina, or
  • hospitalization due to congestive heart failure.
  • Have a history of New York Heart Association Functional Classification III or IV congestive heart failure
  • Have signs and symptoms of liver disease
  • Have a history of pancreatitis
  • Have taken medications or alternative remedies for weight loss or weight gain within 3 months prior to screening

Treatment and study plan

LY3549492

Drug

Administered orally

Placebo

Drug

Administered orally

Primary outcomes

  1. Number of Participants With One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration

    Time frame: Baseline through Week 48

Secondary outcomes

  1. Percent Change From Baseline in Body Weight

    Time frame: Baseline, Week 24, Week 48

  2. Number of Participants With Adverse Events Leading to Permanent Discontinuation of Study Intervention or Withdrawal

    Time frame: Baseline through Week 48

Interested in participating?

Terminated

Looking for future studies?

Notify Me

Sponsors and collaborators

Lead sponsor

Eli Lilly and Company

Industry

Registry information

Official study title

A Parallel-Group, Double-Blind Study to Investigate the Safety and Tolerability of LY3549492 Compared With Placebo in Adult Participants Aged 55 to 80 Years With a BMI of 22 to 25 kg/m2

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Jul 25, 2025
Registry last updated
Sep 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.